Article Cited by others

INVITED REVIEW

Chemotherapy and its evolving role in the management of advanced prostate cancer

Schweizer Michael T, Antonarakis Emmanuel S

Year : 2014| Volume: 16| Issue : 3 | Page no: 334-340

   This article has been cited by
 
1 Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes
Leslimar Ríos-Colón,Christina K. Cajigas-Du Ross,Anamika Basu,Catherine Elix,Ivana Alicea-Polanco,Tino W. Sanchez,Vinodh Radhakrishnan,Chien-Shing Chen,Carlos A. Casiano
Oncotarget. 2017; 8(15): 24915
[Pubmed]  [Google Scholar] [DOI]
2 Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA
Mario Eisenberger,Anne-Claire Hardy-Bessard,Choung Soo Kim,Lajos Géczi,Daniel Ford,Loďc Mourey,Joan Carles,Phillip Parente,Albert Font,Gabriel Kacso,Mustapha Chadjaa,Wenping Zhang,John Bernard,Johann de Bono
Journal of Clinical Oncology. 2017; 35(28): 3198
[Pubmed]  [Google Scholar] [DOI]
3 Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
Laura Graham,Michael T. Schweizer
Medical Oncology. 2016; 33(5)
[Pubmed]  [Google Scholar] [DOI]
4 Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics
Amit Kumar,Tara Mastren,Bin Wang,Jer-Tsong Hsieh,Guiyang Hao,Xiankai Sun
Bioconjugate Chemistry. 2016;
[Pubmed]  [Google Scholar] [DOI]
5 Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer
Jan Kroon,Sander Kooijman,Nam-Joon Cho,Gert Storm,Gabri van der Pluijm
Trends in Pharmacological Sciences. 2016;
[Pubmed]  [Google Scholar] [DOI]

 

Read this article